摘要:目的: 系統評價非布索坦治療痛風的療效及安全性。 方法 :計算機檢索PubMed、EMBASE、SCI、CBM、CNKI、VIP、萬方數據庫及Cochrane圖書館,手工補充檢索;納入非布索坦治療痛風的隨機對照試驗(RCT);進行方法學質量評價和Meta分析。 結果 :共納入3個RCT(受試者1985例),A級文獻1篇,B級文獻2篇。Meta分析結果顯示:最后3月血清尿酸(SU)持續低于60 mg/dl患者數、隨訪結束時SU低于60 mg/dl患者數非布索坦組與對照組差異均有統計學意義;治療相關不良事件發生數與安慰劑組差異無統計學意義,與別嘌呤組差異有統計學意義。 結論 :基于當前證據,非布索坦治療痛風,能有效降低SU含量,減少治療相關不良事件發生率。Abstract: Objective: Assessing the effectiveness and safety of febuxostat for the treatment of gout. Methods :Randomized controlled trails(RCT) of febuxostat for the treatment of gout were gathered from the Cochrane Library、PubMed、EMBASE、SCI、CBM、CNKI、VIP、Wangfang Database, other relative researches were handsearched, each RCT was methodological quality evaluated, then analyzed by software RevMan50 Results :A total of 3 RCTs were collected (involving 1985 subjects); 1 was graded A, 2 were B; according to the Metaanalysis: the differences of subjects with last 3 monthly serum urate(SU)<60mg/dl and subjects with SU<60mg/dl at final visits were significant; treatmentrelated adverse events between febuxostat and allopurinol was significant different, but not significant difference between febuxostat and placebo. Conclusion : According to the evidence currently, febuxostat could reduce SU and the episodes of treatmentrelated adverse events.